GFH375

Phase 3Small molecule

GGenfleet Therapeutics (Shanghai) Inc.

GFH375 is one of 84 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerWithdrawn

Metastatic Pancreatic CancerRecruiting

KRAS G12DRecruiting

Patients With Advanced Solid TumorsRecruiting

Pancreatic CancerPhase 3

Withdrawn

Metastatic Pancreatic CancerPhase 3

Recruiting

KRAS G12DPhase 3

Recruiting

Patients With Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

GFH375

GGenfleet Therapeutics (Shanghai) Inc.

Phase 3

2 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Metastatic Pancreatic Cancer

NCT07262567

Q4 2028

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT06500676

Q3 2029

Phase 2Not yet recruiting

Pancreatic Cancer

NCT07784374

Q2 2031

Phase 3Recruiting

KRAS G12D

NCT07668752

Clinical

Trials by Indication[1]

Pancreatic Cancer2 trials

A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

Withdrawn·GGenfleet Therapeutics (Shanghai) Inc.·Phase 2·NCT07026916

A Phase II, Multicenter, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of GFH375 in Combination With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

Not yet recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 2·NCT07784374·120 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 1/2·NCT06500676·407 enrolled

Metastatic Pancreatic Cancer1 trial

A Multicenter, Open-Label, Randomized Controlled Phase III Study to Compare the Efficacy and Safety/Tolerability of GFH375 Monotherapy Versus Investigator's Choice of Chemotherapy in Patients With Previously Treated KRAS G12D-Mutant Metastatic Pancreatic Cancer

Recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 3·NCT07262567·320 enrolled

KRAS G12D1 trial

A Phase III, Randomized, Open-Label, Multicenter Study to Evaluate GFH375 Versus Docetaxel in Participants With Locally Advanced and Unresectable or Metastatic Non-Small Cell Lung Cancer With KRAS G12D Mutation Failed Prior Standard Therapy

Recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 3·NCT07668752·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GFH375. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GFH375 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GFH375. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genfleet Therapeutics (Shanghai) Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGenfleet Therapeutics (Shanghai) Inc.

GFH375

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Q3 2029

Q2 2031

Trials by Indication[1]

Pancreatic Cancer2 trials

Patients With Advanced Solid Tumors1 trial

Metastatic Pancreatic Cancer1 trial

KRAS G12D1 trial

References

Drug Info

Quick Facts

Related News